Clinical Policy: Vadadustat (Vafseo)
Customize your policy alerts
Sign up for Health Net Policy CP PHAR.677 alerts
Get alerted when Policy CP PHAR.677 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization and continuation criteria for vadadustat (Vafseo) in adults with anemia due to chronic kidney disease who have been receiving dialysis for at least three months; applies to Health Net lines of business including Commercial, HIM, and Medicaid.
Requirement that Vafseo is not prescribed concurrently with Jesduvroq was added.
Continuation of therapy approval duration extended from 6 to 12 months for Medicaid/HIM.
HCPCS code JO901 was added and code C9399 was removed from the policy coding appendix.
Per March SDC, redirection requirement modified to require redirection to both Retacrit and Epogen (if member is unable to use Retacrit).
Added step therapy bypass for Illinois HIM per IL HB 5395.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.